[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, fondaparinux has been explored as a possible bridging agent in the perioperative setting. However, there are limitations to its use as a routine bridging agent, and the role of fondaparinux in perioperative bridge therapy has not been established. Some studies have shown that fondaparinux may be effective in reducing venous thromboembolism, but it is also associated with an increased risk of major bleeding. The use of fondaparinux as a bridging agent should be considered on a case-by-case basis, particularly in patients who cannot use heparin products or have a history of heparin-induced thrombocytopenia. Therefore, the answer to the question is: C. maybe.\", \"answer_choice\": \"C\"}"
]